Scholars Central

Conference abstractPublished 19 Oct 2016

Biosimilars regulations: Updates from Canada

Authors: Oxana Iliach

Quintiles, Canada

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars is still a relatively new and rapidly developing area of biologics; as such there are ongoing changes in regulatory requirements for biosimilars in different countries across the globe. Recent changes in regulatory requirements in USA and EU have definitely attracted much attention and sparked many comments and discussions. In light of changes in these two jurisdictions, the regulatory landscape in Canada is somewhat overlooked. However, a few interesting and exciting changes in regulatory requirements for Subsequent Entry Biologics (SEBs) have occured in Canada in the last year. Examples include the revision of the guidance document âÂ?Â?Information and Submission Requirements for Subsequent Entry Biologics (SEBs)âÂ? and the SEB Scientific Advice Meeting Pilot project. This presentation will address the following questions: Are there more differences than similarities between Health Canada, FDA and EMA regulatory requirements, and what is the future perspective?

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Oxana Iliach”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels